Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Programmed cell death ligand 1 (PD-L1) is a major immune checkpoint protein that mediates antitumor immune suppression and response. Preliminary data suggest that its detection using immunohistochemistry (IHC) in formalin-fixed and paraffin-embedded tissues may predict clinical response to PD-1/PD-L1 therapy. In diagnostic pathology, it is essential to count with a validated IHC that can reliably detect PD-L1-positive cases. The present study was conducted to compare and validate different PD-L1 commercial clones and identify which ones can be reliably used by surgical pathologist to detect PD-L1 expression in human cancer tissues. Eight commercial available PD-L1 clones were tested and compared with a noncommercial PD-L1 antibody clone 5H1. Western blot and IHC using cell lines and human tissues were used to validate these clones. From all PD-L1 antibodies, only the clones E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 passed the Western blot and IHC validation, providing similar pattern than the clone 5H1 and then they were tested in 259 non–small cell lung cancer cases placed in 9 tissue microarrays. Among all cases, only those with ≥2 cores were included (185 cases). Positive and significant correlation was found between the median PD-L1 H-score in tumor and stroma compartments, for all selected antibodies. Overall, 56 of 185 cases were detected as positive cases in malignant cells expressing membranous PD-L1 by all the clones. However, the clone SP263 identified more PD-L1-positive cases compared with the other clones. Our results show that clones E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 provide positive membrane staining pattern comparable with clone 5H1. These commercial clones are comparable, but a careful evaluation by the pathologist is necessary to minimize error of positive misinterpretations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“E1L3N 67 (36) 118 (64) 67 (36) 118 (64) 65 (35) 120 (65) E1J2J 71 (38) 114 (62) 71 (38) 114 (62) 70 (38) 115 (62) SP142 78 (42) 107 (58) 78 (42) 107 (58) 75 (40) 110 (60) 28-8 69 (37) 116 (63) 69 (37) 116 (63) 66 (36) 119 (64) 22C3 68 (37) 111 (63) 68 (37) 111 (63) 64 (34) 121 (66) SP263 89 (48) 92 (52) 89 (48) 92 (52…”
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
PD-L1 Expression in Lung Cancer
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.014 · Cited by 482
Research works printed but not linked: 40
- Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
- Ribas, 2014, The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade, Clin Cancer Res, 20, 4982, 10.1158/1078-0432.CCR-14-0933 · DOI · Paper page
- Carreno, 2002, The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses, Annu Rev Immunol, 20, 29, 10.1146/annurev.immunol.20.091101.091806 · DOI · Paper page
- Sharpe, 2007, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection, Nat Immunol, 8, 239, 10.1038/ni1443 · DOI · Paper page
- Guleria, 2005, A critical role for the programmed death ligand 1 in fetomaternal tolerance, J Exp Med, 202, 231, 10.1084/jem.20050019 · DOI · Paper page
- Watson, 2006, Differential effects of costimulatory pathway modulation on corneal allograft survival, Invest Ophthalmol Vis Sci, 47, 3417, 10.1167/iovs.05-1597 · DOI
- Sugita, 2009, Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism, Invest Ophthalmol Vis Sci, 50, 263, 10.1167/iovs.08-2536 · DOI
- Sheppard, 2004, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3 zeta signalosome and downstream signaling to PKC theta, FEBS Lett, 574, 37, 10.1016/j.febslet.2004.07.083 · DOI · Paper page
- Eggermont, 2014, Cutaneous melanoma, Lancet, 383, 816, 10.1016/S0140-6736(13)60802-8 · DOI · Paper page
- Droeser, 2013, Clinical impact of programmed cell death ligand 1 expression in colorectal cancer, Eur J Cancer, 49, 2233, 10.1016/j.ejca.2013.02.015 · DOI · Paper page
- Ghebeh, 2006, The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, 8, 190, 10.1593/neo.05733 · DOI · Paper page
- Bigelow, 2013, Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue, J Vis Exp, 71, e4059
- Lin, 2014, Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for non-small cell lung cancer, Zhongguo fei ai za zhi, 17, 734
- Parra, 2016, Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients, Clin Cancer Res, 22, 6278, 10.1158/1078-0432.CCR-15-2443 · DOI · Paper page
- Sznol, 2013, Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer—response, Clin Cancer Res, 19, 1021, 10.1158/1078-0432.CCR-12-2063 · DOI · Paper page
- Berghoff, 2014, PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL), Clin Neuropathol, 33, 42, 10.5414/NP300698 · DOI · Paper page
- Bordeaux, 2010, Antibody validation, Biotechniques, 48, 197, 10.2144/000113382 · DOI · Paper page
- Rimm, 2014, Unvalidated antibodies and misleading results, Breast Cancer Res Treat, 147, 457, 10.1007/s10549-014-3061-0 · DOI
- Ilie, 2016, Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients, Virchows Arch, 468, 511, 10.1007/s00428-016-1910-4 · DOI · Paper page
- Boland, 2013, Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung, Clin Lung Cancer, 14, 157, 10.1016/j.cllc.2012.05.006 · DOI · Paper page
- Kim, 2015, Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers, Lung Cancer, 88, 24, 10.1016/j.lungcan.2015.01.016 · DOI · Paper page
- Guo, 2013, Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC, J Thorac Oncol, 8, 301, 10.1097/JTO.0b013e318282def7 · DOI
- Howat, 2014, Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers, Methods, 70, 34, 10.1016/j.ymeth.2014.01.018 · DOI · Paper page
- Algenas, 2014, Antibody performance in western blot applications is context-dependent, Biotechnol J, 9, 435, 10.1002/biot.201300341 · DOI
- Thompson, 2005, B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma, Urology, 66, 10, 10.1016/j.urology.2005.06.010 · DOI
- Thompson, 2007, Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy, Clin Cancer Res, 13, 709s, 10.1158/1078-0432.CCR-06-1868 · DOI · Paper page
- Karim, 2009, Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma, Clin Cancer Res, 15, 6341, 10.1158/1078-0432.CCR-09-1652 · DOI · Paper page
- Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Curr Opin Immunol, 24, 207, 10.1016/j.coi.2011.12.009 · DOI · Paper page
- Kerr, 2016, Non-small cell lung cancer, PD-L1, and the pathologist, Arch Pathol Lab Med, 140, 249, 10.5858/arpa.2015-0303-SA · DOI · Paper page
- Konishi, 2004, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin Cancer Res, 10, 5094, 10.1158/1078-0432.CCR-04-0428 · DOI · Paper page
- Velcheti, 2014, Programmed death ligand-1 expression in non-small cell lung cancer, Lab Invest, 94, 107, 10.1038/labinvest.2013.130 · DOI · Paper page
- Kerr, 2015, Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?, J Thorac Oncol, 10, 985, 10.1097/JTO.0000000000000526 · DOI · Paper page
- D'Incecco, 2015, PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br J Cancer, 112, 95, 10.1038/bjc.2014.555 · DOI · Paper page
- Yang, 2014, Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes, Eur J Cancer, 50, 1361, 10.1016/j.ejca.2014.01.018 · DOI · Paper page
- Gatalica, 2014, Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type, Cancer Epidemiol Biomarkers Prev, 23, 2965, 10.1158/1055-9965.EPI-14-0654 · DOI · Paper page
- Smith, 2016, Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N, Diagn Pathol, 11, 44, 10.1186/s13000-016-0494-2 · DOI
- Karlsson, 2011, Effects of long-term storage on the detection of proteins, DNA, and mRNA in tissue microarray slides, J Histochem Cytochem, 59, 1113, 10.1369/0022155411423779 · DOI
- Cree, 2016, PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation, Histopathology, 69, 177, 10.1111/his.12996 · DOI
- Sholl, 2016, Programmed death ligand-1 immunohistochemistry—a new challenge for pathologists: a perspective from members of the Pulmonary Pathology Society, Arch Pathol Lab Med, 140, 341, 10.5858/arpa.2015-0506-SA · DOI
- Rehman, 2017, Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer, Modern Pathol, 30, 340, 10.1038/modpathol.2016.186 · DOI · Paper page
Cited by
Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01224-2 · Cited by 618
Self-citationParra, E. R., Uraoka, N., Jiang, M., Cook, P., Gibbons, D., Forget, M.-A., Bernatchez, C., Haymaker, C., Wistuba, I. I., & Rodriguez-Canales, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-13942-8 · Cited by 266
Self-citationKeung, E. Z., Burgess, M., Salazar, R., Parra, E. R., Rodrigues-Canales, J., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Attia, S., Riedel, R. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1824 · Cited by 215
Self-citationPawelczyk, K., Piotrowska, A., Ciesielska, U., Jablonska, K., Glatzel-Plucinska, N., Grzegrzolka, J., Podhorska-Okolow, M., Dziegiel, P., & Nowinska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040824 · Cited by 192
“The expression of PD-L1 in macrophages and lymphocytes is typical and was also observed in other studies [5].”
BackgroundResultInfluentialTremblay-LeMay, R., Rastgoo, N., & Chang, H. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0589-1 · Cited by 69
Metadata
- Authors
- Parra, E. R., Villalobos, P., Mino, B., & Rodriguez-Canales, J.
- Venue
- Applied Immunohistochemistry & Molecular Morphology
- Published
- 2018-02
- Volume
- 26
- Issue
- 2
- Pages
- 83-93
- ISSN
- 1533-4058 (ISSN-L)
- 1541-2016
- OpenAlex
- W2738111927
- Cited by
- 155
- References
- 11
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma. https://app.cochat.ai/papers/10.1097/pai.0000000000000531
- The paper
- Parra, E. R., Villalobos, P., Mino, B., & Rodriguez-Canales, J. (2018). Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma. Applied Immunohistochemistry & Molecular Morphology. https://doi.org/10.1097/pai.0000000000000531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.